Literature DB >> 33426646

Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten-year follow-up.

Woldesellassie M Bezabhe1, Luke R Bereznicki1, Jan Radford2, Barbara C Wimmer1, Mohammed S Salahudeen1, Edward Garrahy2, Ivan Bindoff1, Gregory M Peterson1.   

Abstract

AIM: To examine the change in stroke risk over time and determine the proportion of patients with atrial fibrillation (AF) who were initiated on an oral anticoagulant (OAC) as their stroke risk increased from low/moderate to high, using the Australian general practice data set, MedicineInsight.
METHODS: A total of 2296 patients diagnosed with AF between 1 January 2007 and 31 December 2008, aged 18 years or older and not initiated on an OAC before 2009, were included. We assessed the change in stroke risk and the proportion of patients who had a recorded prescription of an OAC, each year from 1 January 2009 to 31 December 2018.
RESULTS: At baseline, 23.9%, 22.9% and 53.2% were categorised as being at low (score = 0), moderate (score = 1) and high stroke risk (score ≥ 2), respectively, using the sexless CHA2 DS2 -VASc (CHA2 DS2 -VA) score. Overall, the CHA2 DS2 -VA score increased by a mean of 1.34 (95% confidence interval, 1.29-1.39) points over the study period. Nearly two-thirds of patients (65%, 412/632) whose stroke risk changed from baseline low/moderate to high were subsequently prescribed an OAC. The median (interquartile range) lag time from becoming high stroke risk to having OAC initiation was 2 (5) years.
CONCLUSIONS: Nearly one-third of patients reclassified as being at high risk of stroke during the study period were not prescribed OAC therapy. Furthermore, the delay in OAC initiation following classification as being at high risk was a median of 2 years, suggesting that more frequent stroke reassessment is needed.
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Australia; anticoagulation; atrial fibrillation; ischaemic stroke; primary care; reassessment

Mesh:

Substances:

Year:  2021        PMID: 33426646     DOI: 10.1111/eci.13489

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  5 in total

1.  Predicted cardiovascular disease risk and prescribing of antihypertensive therapy among patients with hypertension in Australia using MedicineInsight.

Authors:  Jacqueline Roseleur; David A Gonzalez-Chica; Jonathan Karnon; Nigel P Stocks
Journal:  J Hum Hypertens       Date:  2022-05-02       Impact factor: 3.012

2.  Comments: Absolute cardiovascular risk assessment for guiding antihypertensive prescribing in Australian primary care patients with hypertension.

Authors:  Woldesellassie M Bezabhe; Gregory M Peterson
Journal:  J Hum Hypertens       Date:  2022-07-06       Impact factor: 3.012

3.  Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019.

Authors:  Iwona Gorczyca-Głowacka; Bernadetta Bielecka; Paweł Wałek; Magdalena Chrapek; Agnieszka Ciba-Stemplewska; Olga Jelonek; Anna Kot; Anna Czyżyk; Maciej Pióro; Agnieszka Major; Beata Wożakowska-Kapłon
Journal:  Int J Environ Res Public Health       Date:  2022-05-04       Impact factor: 4.614

4.  Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population-Based Cohort Study.

Authors:  Woldesellassie M Bezabhe; Luke R Bereznicki; Jan Radford; Barbara C Wimmer; Mohammed S Salahudeen; Edward Garrahy; Ivan Bindoff; Gregory M Peterson
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 6.106

5.  Use of thromboprophylaxis guidelines and risk stratification tools in atrial fibrillation: A survey of general practitioners in Australia.

Authors:  Eyob Alemayehu Gebreyohannes; Sandra M Salter; Leanne Chalmers; Jan Radford; Kenneth Lee
Journal:  J Eval Clin Pract       Date:  2022-04-06       Impact factor: 2.336

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.